Silenseed is a clinical stage biopharmaceutical company established in 1999 with a focus on developing proprietary RNA interference (RNAi)-based cancer drugs and advanced delivery systems. The company's innovative drugs, in conjunction with the newly developed delivery system LODER™ (LOcal Drug EluteR), hold significant promise for providing highly effective treatment options for solid tumor cancers. Silenseed's research and development pipeline includes pancreatic cancer, prostate cancer, and certain types of brain cancers. The company recently secured a Series A investment on 01 December 2020 from Laursen van Swieten. Silenseed operates within the industries of Biopharma, Biotechnology, and Health Care.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | Unknown | 1 |
|
01 Dec 2020 |
| Venture Round | $10.00M | - | 01 Aug 2017 | |
| Venture Round | $500.00K | - | 08 Apr 2014 |
No recent news or press coverage available for Silenseed.
We care about your data, and we'd love to use cookies make your experience better.
